6/27/2013 8:04:33 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
In the latest sign that drugmakers are trying to save costs by working together, Roche and AstraZeneca (AZN) signed a deal to share data on early-stage drug design in hopes of speeding development. As part of the collaboration, the drugmakers will actually contribute their data to MedChemica, which specializes in scrutinizing chemical compounds for structures that can cause problems with safety or effectiveness. We spoke with Luca Santarelli, senior vice president, head of small molecule research and neuroscience at Roche, about the reasons for the deal and the potential opportunities. This is an edited version...
Help employers find you! Check out all the jobs and post your resume.
comments powered by